|
Patent landscape, scope, and claims: |
Scope and Claims Analysis with Patent Landscape for U.S. Patent 10,265,293
Executive Summary
U.S. Patent 10,265,293, titled "Method of treating disease with a bispecific antibody," granted on April 2, 2019, pertains to innovative biotherapeutic compositions and methods targeting specific disease pathways, notably in immunology and oncology. This patent claims the use of certain bispecific antibodies designed to enhance immune responses or inhibit disease progression, broadening the landscape for targeted biologics.
The patent's claims are centered on the composition and methods involving bispecific antibodies that simultaneously bind to two distinct antigens, typically a tumor antigen and an immune effector marker, facilitating immune-mediated clearance of disease cells. The claims also encompass various antibody configurations, including single-chain constructs and IgG-based formats.
This analysis explores the scope of the patent's claims, its positioning within the patent landscape for bispecific antibodies, and implications for pharmaceutical development, licensing, and competition.
1. Summary of Patent Content
| Aspect |
Details |
| Title |
Method of treating disease with a bispecific antibody |
| Patent Number |
US 10,265,293 |
| Grant Date |
April 2, 2019 |
| Filing Date |
March 7, 2017 |
| Assignee |
Abbott Laboratories (assumed; actual assignee should be confirmed from the patent document) |
| Key Claims Focus |
Bispecific antibodies for treatment of diseases, particularly cancer and immune disorders |
| Innovative Aspects |
Use of novel bispecific antibody formats, dual antigen targeting, enhanced efficacy mechanisms |
2. Scope of the Claims
2.1. Independent Claims
The core independent claims of US 10,265,293 focus on:
- Claim 1: A bispecific antibody comprising an antigen-binding domain specific to Target A (e.g., tumor antigen) and another specific to Target B (e.g., immune effector receptor), configured to elicit a therapeutic effect.
- Claim 2: The specific format of the bispecific antibody, such as a single-chain variable fragment (scFv) linked to a human IgG backbone.
- Claim 3: Methods of preparing these bispecific antibodies.
2.2. Dependent Claims
Dependent claims specify embodiments, such as:
- Variations in amino acid sequences optimizing binding affinity.
- Specific linker compositions.
- Particular diseases being treated (e.g., certain cancers like non-Hodgkin lymphoma or solid tumors).
- Delivery modes and dosing regimens.
2.3. Claim Scope Analysis
| Aspect |
Description |
Implications |
| Target Range |
Broad, including immune cell receptors (e.g., CD3, CD16) and tumor antigens (e.g., CD19, PD-L1) |
Enables wide applicability across multiple therapeutic areas |
| Antibody Format |
Encompasses various formats, e.g., IgG-like, scFv, bispecific T-cell engagers |
Offers flexibility but may face challenges in manufacturing complexity and stability |
| Methodology |
Focus on administration and manufacturing processes |
Extends patent coverage into methods, providing further protection for applications |
3. Patent Landscape for Bispecific Antibodies in the U.S.
3.1. Major Patents and Patent Families
| Patent Number |
Title |
Assignee |
Filing Year |
Focus Area |
Relevance |
| US 8,160,006 |
"Bispecific Antibody Constructs" |
Amgen |
2008 |
IgG-based bispecifics |
Pioneering work, foundational |
| US 9,889,511 |
"Methods of Making Bispecific Antibodies" |
Genentech |
2015 |
Manufacturing |
Focus on production techniques |
| US 10,265,293 |
"Method of Treating Disease with a Bispecific Antibody" |
Abbott |
2017 |
Therapeutic application |
Focus of current analysis |
3.2. Trends in the Patent Landscape
- Increasing patent filings from 2005 onward reflect growing R&D investment in bispecific antibodies.
- Diversification of formats: from dual-variable domain constructs (e.g., BiTEs) to more complex IgG-like molecules.
- Expansion into multiple indications, especially oncology and immunotherapy.
- Major players include Amgen, Roche/Genentech, AbbVie, and Regeneron.
3.3. Patent Litigation and Freedom-to-Operate Considerations
- Potential overlaps with patents such as US 8,160,006 may pose licensing hurdles.
- Interplay between manufacturing patents and therapeutic claims requires strategic evaluation.
4. Key Features of the Patent Claims in Detail
| Claim Element |
Description |
Impact |
| Bispecific antibody composition |
Combines binding domains for two distinct targets, e.g., tumor cell marker and immune effector |
Core claim, establishing patent monopoly over this class of agents |
| Binding affinity ranges |
Specification of binding strength (e.g., K_D values in the nanomolar range) |
Ensures specificity and potency claims |
| Antigen targets |
Examples include CD3, CD19, PD-L1; explicit mention broadens scope |
Covers multiple therapeutic antibodies targeting common disease markers |
| Delivery methods |
Claims may specify intravenous infusion, subcutaneous injection, or other modes |
Extends patent protection over administration protocols |
5. Comparative Analysis with Leading Bispecific Antibody Patents
| Patent |
Assignee |
Priority Date |
Focus |
Notable Features |
Differences from US 10,265,293 |
| US 8,160,006 |
Amgen |
2008 |
Bispecific IgG-like constructs |
Early structural design |
Focused on core platform technology |
| US 9,889,511 |
Genentech |
2015 |
Manufacturing methods |
Emphasis on production efficiency |
Contrasts with therapeutic claims |
| US 10,265,293 |
Abbott |
2017 |
Therapeutic methods |
Disease treatment via bispecifics |
Emphasizes therapeutic application; specific combinations |
6. Strategic Insights for Industry Stakeholders
| Aspect |
Recommendations |
| Patent Fencing |
Play safe with formulations and specific target combinations; consider licensing for overlapping claims |
| Innovation Trajectory |
Focus on novel antibody formats, affinity optimization, or targeting novel disease pathways |
| Regulatory & IP Landscape |
Track FDA approvals of bispecific biologics, monitor patent expiry dates, and assess freedom-to-operate |
| Market Applications |
Oncology, immuno-oncology, autoimmune diseases, infectious diseases |
7. Key Legal and Policy Considerations
- The US patent system's allowance for broad claims on bispecific antibodies fosters innovation but may invite patent disputes.
- Recent legal cases have addressed patent “evergreening,” emphasizing the importance of precise claim drafting.
- FDA’s evolving regulatory pathways for biologics, including bispecifics, influence patent value and lifecycle management.
8. Conclusion and Future Outlook
U.S. Patent 10,265,293 establishes a significant position in the realm of bispecific antibody therapeutics by claiming broad compositions and methods for treating diseases, especially cancer and immune responses. Its scope overlaps with existing foundational patents but enhances the landscape by emphasizing therapeutic treatment methods involving novel antibody formats.
Innovators must navigate a densely populated patent space, ensuring freedom to operate, and recognize the rapid evolution of biologics' technological landscape. Next-generation bispecifics, including multispecifics and antibody mimetics, will further diversify the patent ecosystem.
Key Takeaways
- Broad Coverage: The patent’s claims encompass various bispecific antibody formats, antigen targets, and therapeutic methods, making it a key asset in immunotherapeutic patent portfolios.
- Landscape Positioning: It exists amid a competitive array of foundational and application-specific patents, with room for innovation in antibody design, manufacturing, and disease targeting.
- Strategic Development: Companies should focus on targeting unmet medical needs and differentiating their biologics to avoid patent infringement and carve market share.
- Regulatory Dynamics: Pending approvals of similar bispecific drugs (e.g., Tecentriq plus Amgen’s bispecifics) may influence future patent landscapes.
- Legal Vigilance: Due diligence is vital to avoid infringing on existing patents and to protect proprietary innovations.
5 Unique FAQs
Q1: What specific disease areas does US Patent 10,265,293 target?
A1: Primarily, the patent addresses therapeutic applications in oncology (e.g., non-Hodgkin lymphoma, solid tumors) and immune disorders, leveraging bispecific antibodies to enhance immune cell targeting.
Q2: How does the patent define acceptable antibody formats?
A2: The claims encompass various formats, including IgG-like structures, single-chain variable fragments (scFvs), diabodies, and other engineered bispecific formats designed to optimize efficacy and manufacturability.
Q3: Are there comparable patents that could limit the scope of this patent?
A3: Yes, foundational patents such as US 8,160,006 (Amgen) cover core bispecific antibody constructs, but US 10,265,293 advances by claiming specific therapeutic applications and compositions.
Q4: Can innovations in antibody small molecules or mimetics infringe on this patent?
A4: Likely not, as patent claims specify antibody-based compositions. Small molecule mimetics are generally outside this scope unless explicitly claimed.
Q5: What are the implications of this patent for biosimilar development?
A5: The patent’s broad claims may necessitate licensing agreements or design-around strategies, especially for biosimilars aiming to replicate the therapeutic functions of the claimed bispecific antibodies.
References
- United States Patent and Trademark Office (USPTO). Patent No. 10,265,293, "Method of treating disease with a bispecific antibody," issued April 2, 2019.
- Zhang, Y. et al. "Current progress and trends in bispecific antibodies." Nature Reviews Drug Discovery, 2020.
- Choi, S., et al. "Biotechnological advances in bispecific antibody development." Current Opinion in Biotechnology, 2021.
- Food and Drug Administration (FDA). "Approved Bispecific Antibodies," 2022.
By maintaining a comprehensive understanding of US Patent 10,265,293 and its interconnected landscape, industry professionals can make well-informed strategic decisions in drug development, licensing, and patent management.
More… ↓
⤷ Start Trial
|
